Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues
Japanese pharmaceutical corporation Astellas Pharma Inc., (TYO: 4503) has announced its financial results for the...
Astellas Pharma
Astellas Forges Partnership with Mass General Brigham to Boost Oncology and Rare Disease Research
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced a strategic partnership...
Astellas Pharma Appoints Zhao Ping as Chairman of China Operations
Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed...
Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies
The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...
Elpiscience Partners with Astellas for Bi-Specific Macrophage Engager Research
China-based Elpiscience Biopharmaceuticals has announced a research collaboration and licensing agreement with Japan’s Astellas Pharma...
Pfizer and Astellas Pharma Secure FDA Approval for Xtandi in High-Risk Non-Metastatic Prostate Cancer
Partners Pfizer (NYSE: PFE) and Astellas Pharma (TSE: 4503) last week received indication extension approval...
Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment
Japan’s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US...
Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials
Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half...
Astellas Pharma’s Xtandi NDA for mHSPC Treatment Accepted by China’s CDE
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...
Astellas Pharma Invests EUR 330 Million in State-of-the-Art Manufacturing Plant in Ireland
Japanese pharmaceutical company Astellas Pharma (TYO: 4503) has announced a significant investment of EUR 330...
EMA Approves Astellas’ Xtandi for Non-Metastatic Hormone-Sensitive Prostate Cancer
The European Medicines Agency (EMA) has granted Japan-based Astellas (TYO: 4503) an indication extension approval...
Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition...
FDA Grants Priority Review to Pfizer and Astellas’ Xtandi for High-Risk Prostate Cancer
The US Food and Drug Administration (FDA) has granted priority review status to the submission...
Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy
US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...
Astellas Pharma’s Izervay Receives FDA Approval for Geographic Atrophy Treatment
Japan-based Astellas Pharma Inc., (TYO: 4503) has announced that it has received new market approval...
Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...
Baheal Pharmaceutical Partners with RabPharma for Commercialization of RAB001 in China
China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...
Astellas Pharma Executive Arrested in China on Spying Allegations
A Japanese national and executive at the Chinese division of Tokyo-based Astellas Pharma Inc. (TYO:...
Astellas Pharma’s Xtandi Gains Momentum in China with Positive Phase III ARCHES Study Results
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that its prostate cancer therapy, Xtandi (enzalutamide),...
Astellas and Seagen File for NMPA Approval of Enfortumab Vedotin for Urothelial Carcinoma
Japan-based Astellas Pharma Inc. (TYO: 4503) and US biotech Seagen Inc. (Nasdaq: SGEN) have announced...